{"title":"佩拉嗪治疗急性精神分裂症的预测及评价标准。方法学考虑、样本总体和研究变量。","authors":"W Rein, H W Schied, U Breyer-Pfaff, E Straube","doi":"10.1055/s-2007-1019489","DOIUrl":null,"url":null,"abstract":"Summary In an open study of schizophrenic patiants traated with perazine (Taxilan®), a multidimensional approach compris ing the following three areas was chosen:","PeriodicalId":19840,"journal":{"name":"Pharmacopsychiatria","volume":"16 5","pages":"147-51"},"PeriodicalIF":0.0000,"publicationDate":"1983-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-2007-1019489","citationCount":"2","resultStr":"{\"title\":\"Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Methodological considerations, sample population, and research variables.\",\"authors\":\"W Rein, H W Schied, U Breyer-Pfaff, E Straube\",\"doi\":\"10.1055/s-2007-1019489\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary In an open study of schizophrenic patiants traated with perazine (Taxilan®), a multidimensional approach compris ing the following three areas was chosen:\",\"PeriodicalId\":19840,\"journal\":{\"name\":\"Pharmacopsychiatria\",\"volume\":\"16 5\",\"pages\":\"147-51\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1983-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1055/s-2007-1019489\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacopsychiatria\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-2007-1019489\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacopsychiatria","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-2007-1019489","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Methodological considerations, sample population, and research variables.
Summary In an open study of schizophrenic patiants traated with perazine (Taxilan®), a multidimensional approach compris ing the following three areas was chosen: